AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING ...
Download
1 / 18

G. BIONDI-ZOCCAI1, C. MORETTI1, E. MELIGA1, P. AGOSTONI2, - PowerPoint PPT Presentation


  • 51 Views
  • Uploaded on

AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE. G. BIONDI-ZOCCAI1, C. MORETTI1, E. MELIGA1, P. AGOSTONI2, M. VALGIMIGLI3, A. ABBATE4, G. SANGIORGI5, G. TREVI1 AND I. SHEIBAN1

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' G. BIONDI-ZOCCAI1, C. MORETTI1, E. MELIGA1, P. AGOSTONI2, ' - jolene-moon


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE

G. BIONDI-ZOCCAI1, C. MORETTI1, E. MELIGA1, P. AGOSTONI2,

M. VALGIMIGLI3, A. ABBATE4, G. SANGIORGI5, G. TREVI1

AND I. SHEIBAN1

1University of Turin, Turin, Italy (gbiondizoccai@gmail.com); 2AZ Middelheim, Antwerp, Belgium; 3University of Ferrara, Ferrara, Italy; 4Virginia Commonwealth University,

Virginia, USA; 5Emo Centro Cuore Columbus, Milano,Italy


Background
BACKGROUND PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE

  • Cardiac surgery is the gold standard revascularization means for unprotected left main disease (ULM)

  • Percutaneous drug-eluting stent (DES) implantation has been recently reported in patients with ULM, but with unclear results. We thus sought to systematically review the outcomes of DES implantation in patients with ULM coronary disease


Objectives
OBJECTIVES PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE

  • To perform a systematic review of the outcomes of DES implantation in patients with ULM coronary disease

  • To pool major outcomes with meta-analytic techniques


Methods
METHODS PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE

  • Several databases (BioMedCentral, clinicaltrials.gov, Google Scholar, and PubMed) were systematically searched for pertinent clinical studies published up to November 2006

  • Major selection criteria were:

    • enrolment of at least 20 patients

    • follow-up for at least 6 months

    • full text publication (thus excluding abstracts)


Methods1
METHODS PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE

  • Pre-specified subgroup analyses were performed according to ostial ULM, and non-high-risk features (defined by means of Parsonnet or EuroSCORE systems)

  • Generic-inverse-variance random-effect methods were used to pool incidence rates and adjusted risk estimates (odds ratios [OR], with 95% confidence intervals) of death, myocardial infarction (MI), target vessel revascularization (TVR), or their composite, ie major adverse cardiovascular events (MACE)


Review profile
REVIEW PROFILE PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE


Results
RESULTS PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE

  • After excluding 806 non-pertinent citations, we finally included 16 original studies (1274 patients, median follow-up 9 months [range 6-24])

  • There were 8 uncontrolled reports on DES, 5 non-randomized comparison between DES and bare-metal stents (BMS), and 3 between DES and CABG, with a median follow-up of 10 months


Included studies
INCLUDED STUDIES PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE


Patient and procedural characteristics
PATIENT AND PROCEDURAL CHARACTERISTICS PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE


Design and quality
DESIGN AND QUALITY PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE


Risk of in hospital death
RISK OF IN-HOSPITAL DEATH PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE


Risk of in hospital mi
RISK OF IN-HOSPITAL MI PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE


Risk of mace at follow up
RISK OF MACE AT FOLLOW-UP PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE


Risk of death at follow up
RISK OF DEATH AT FOLLOW-UP PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE


Risk of tvr at follow up
RISK OF TVR AT FOLLOW-UP PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE


Non randomized comparisons
NON-RANDOMIZED COMPARISONS PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE

  • Multivariable adjusted estimates for the DES vs BMS comparison were reported only by a handful of studies, for a total of 206 patients treated with DES vs 190 with bare-metal stents (BMS). Pooled analysis showed the superiority of DES both in terms of follow-up MACE and TVR (respectively OR=0.34 [0.16-0.71], p=0.004, and OR=0.34 [0.12-0.94], p=0.04)

  • Adjusted estimates for the DES-based PCI vs CABG were reported only by Chieffo et al and Lee et al for a total of 157 patients treated with DES and 265 with CABG. Meta-analysis for the occurrence of MACCE (ie MACE plus stroke) at follow-up, suggested the superiority of DES vs CABG (OR=0.46 [0.24-0.90], p=0.02), even if this estimate should be viewed with caution


Conclusions
CONCLUSIONS PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE

  • The largest cohort reported to date of patients with ULM treated with DES provides encouraging mid-term follow-up data, at least in selected patients

  • Whether long-term outlook is also favourable needs to be established by longer clinical follow-up of currently available registries and ongoing randomized trials of DES vs CABG


For further slides on these topics please feel free to visit the metcardio.org website:http://www.metcardio.org/slides.html